NECTAR LIFESCIENCES LTD. (NECLIFE) financials

NECTAR LIFESCIENCES LTD. (NECLIFE) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]

Market Cap: ₹205Cr.
Current Price: ₹10.5
ROE: -31.3%
ROCE: 0.05%
Book Value: ₹30.0
Dividend Yield: 0.00%
52W High / Low: ₹22.5/9.20

In Jun 2026, NECTAR LIFESCIENCES LTD. (NECLIFE) reported sales ₹0 Cr and net profit ₹-13 Cr.

Annual TTM: sales ₹7 Cr, net profit ₹-243 Cr.

Shareholding: Promoters 51.84% (Sep 2026), FIIs 0.50% (Sep 2026), DIIs 0.00% (Sep 2026), Government 3.92% (Sep 2026), Public 43.74% (Sep 2026).

NECLIFE quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	6	455	0	5	6	-0	1	0
Expenses	6	410	0	6	6	2	59	28
Operating Profit	-1	45	-0	-1	-0	-2	-57	-27
OPM %	-10%	10%	-500%	-16%	-6%	—	-4,436%	-6,189%
Other Income	7	1	-130	-62	-176	35	-24	6
Interest	-0	17	-0	-0	-0	30	6	0
Depreciation	0	16	0	1	0	0	0	0
Profit before tax	5	13	-130	-64	-176	3	-88	-21
Tax %	-2%	38%	-0%	-1%	-0%	-339%	-22%	-38%
Net Profit	6	8	-130	-63	-176	14	-68	-13
EPS in Rs	0.25	0.35	-5.80	-2.82	-7.85	0.64	-3.50	-0.68
Raw PDF	—	—	—	—	—	—	—	—

NECLIFE profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	2,360	1,539	1,664	1,522	1,682	-0	-0	7
Expenses	2,142	1,430	1,506	1,467	1,530	0	8	94
Operating Profit	218	109	159	55	152	-0	-8	-87
OPM %	9%	7%	10%	3.6%	9%	-12%	-2,919%	-1,166%
Other Income	4	-22	11	43	15	-112	-279	-158
Interest	126	112	79	79	87	-0	36	36
Depreciation	61	60	57	59	61	1	0	0
Profit before tax	36	-85	34	-41	18	-113	-323	-282
Tax %	16%	-14%	26%	-45%	73%	0%	-9%	—
Net Profit	30	-73	25	-22	5	-114	-293	-243
EPS in Rs	1.34	-3.26	1.13	-1.00	0.22	-5.07	-15.08	-11.39
Dividend Payout %	4%	-0%	-0%	-0%	-0%	-0%	-0%	—

NECLIFE balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22	22	22	22	22	22	22	19
Reserves	1,082	1,112	1,038	1,064	1,042	1,047	934	563
Borrowings	903	779	903	860	754	636	582	-0
Other Liabilities	696	719	423	443	371	486	509	30
Total Liabilities	2,704	2,632	2,387	2,390	2,189	2,191	2,047	612
Fixed Assets	825	785	772	723	662	643	633	3
CWIP	100	115	99	85	78	66	57	-0
Investments	1	1	1	1	1	1	1	13
Other Assets	1,778	1,732	1,515	1,580	1,449	1,482	1,357	595
Total Assets	2,704	2,632	2,387	2,390	2,189	2,191	2,047	612

NECLIFE cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	239	286	21	95	133	225	169	-417
Cash from Investing Activity	-26	-33	-29	17	52	-17	-42	1,205
Cash from Financing Activity	-201	-252	11	-119	-186	-205	-128	-699
Net Cash Flow	12	1	4	-8	-0	2	-1	89
Free Cash Flow	203	249	-10	110	183	195	126	-408
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	96%	135%	23%	60%	244%	148%	-89,179%	4,951%

NECLIFE shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	44.53%	44.53%	44.53%	44.91%	44.91%	51.84%	51.84%	51.84%
FIIs	0.73%	1.65%	0.82%	0.62%	0.52%	0.60%	0.50%	0.50%
DIIs	0.00%	0.15%	0.19%	0.08%	0.00%	0.01%	0.01%	0.00%
Government	0.02%	0.02%	0.02%	0.02%	5.84%	4.03%	3.75%	3.92%
Public	54.72%	53.64%	54.45%	54.37%	48.73%	43.52%	43.90%	43.74%
No. of Shareholders	69,482	69,241	71,977	76,470	78,124	74,834	73,834	72,334

NECLIFE key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	74	61	89	98	67	82	—	—
Inventory Days	150	192	185	197	212	215	—	—
Days Payable	79	104	108	112	100	127	—	—
Cash Conversion Cycle	145	149	166	183	178	170	—	—
Working Capital Days	46	53	6	73	77	63	—	—
ROCE %	10%	8%	3%	5%	-0%	6%	0%	0%

NECLIFEUpdated 18 Oct 2026, 8:39

Nectar Lifesciences Ltd.

NECLIFEUpdated 18 Oct 2026, 8:39

Market Cap

₹205Cr.

Current Price

₹10.5

High / Low

₹22.5/9.20

ROE-31.3%

ROCE0.05%

Book Value₹30.0

Face Value₹1.00

Dividend Yield0.00%

About

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	394	18	359	0	15	3	41	2	0.08
Sep 2023	398	21	371	11	15	2	38	1	0.05
Dec 2023	452	25	410	0	15	2	36	2	0.07
Mar 2024	441	24	393	1	15	11	95	1	0.03
Jun 2024	359	20	319	1	15	5	40	3	0.13
Sep 2024	6	0	6	7	0	5	-2	6	0.25
Dec 2024	455	17	410	1	16	13	38	8	0.35
Mar 2025	0	0	0	-130	0	-130	0	-130	-5.8
Jun 2025	5	0	6	-62	1	-64	-1	-63	-2.82
Sep 2025	6	0	6	-176	0	-176	0	-176	-7.85
Dec 2025	0	30	2	35	0	3	-339	14	0.64
Mar 2026	1	6	59	-24	0	-88	-22	-68	-3.5
Jun 2026	0	0	28	6	0	-21	-38	-13	-0.68

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	1638	126	1371	20	77	85	22	66	2.95
Mar 2016	1675	123	1436	6	57	64	15	54	2.42
Mar 2017	1635	117	1411	23	62	67	18	55	2.46
Mar 2018	1873	115	1637	6	64	63	17	52	2.33
Mar 2019	2781	148	2517	6	63	59	19	47	2.11
Mar 2020	2360	126	2142	4	61	36	16	30	1.34
Mar 2021	1539	112	1430	-22	60	-85	-14	-73	-3.26
Mar 2022	1664	79	1506	11	57	34	26	25	1.13
Mar 2023	1522	79	1467	43	59	-41	-45	-22	-1
Mar 2024	1682	87	1530	15	61	18	73	5	0.22
Mar 2025	0	0	0	-112	1	-113	0	-114	-5.07
Mar 2026	0	36	8	-279	0	-323	-9	-293	-15.08
TTM	7	36	94	-158	0	-282	—	-243	-11.39

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	51.84%
FIIs	0.5%
Government	3.92%
Public	43.74%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	55.8%	16.12%	0%	0.02%	28.05%
Mar 2024	55.8%	16.98%	0%	0.02%	27.2%
Jun 2024	55.8%	16.6%	0%	0.02%	27.57%
Sep 2024	55.8%	3.24%	0%	0.02%	40.94%
Dec 2024	44.53%	0.73%	0%	0.02%	54.72%
Mar 2025	44.53%	1.65%	0.15%	0.02%	53.64%
Jun 2025	44.53%	0.82%	0.19%	0.02%	54.45%
Sep 2025	44.91%	0.62%	0.08%	0.02%	54.37%
Dec 2025	44.91%	0.52%	0%	5.84%	48.73%
Mar 2026	51.84%	0.6%	0.01%	4.03%	43.52%
Jun 2026	51.84%	0.5%	0.01%	3.75%	43.9%
Sep 2026	51.84%	0.5%	0%	3.92%	43.74%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	22	936	925	628	2510	934	91	1	1485	2510
Mar 2016	22	932	962	640	2557	906	99	1	1551	2557
Mar 2017	22	984	878	696	2581	881	102	1	1597	2581
Mar 2018	22	1036	955	710	2724	852	100	1	1771	2724
Mar 2019	22	1082	903	696	2704	825	100	1	1778	2704
Mar 2020	22	1112	779	719	2632	785	115	1	1732	2632
Mar 2021	22	1038	903	423	2387	772	99	1	1515	2387
Mar 2022	22	1064	860	443	2390	723	85	1	1580	2390
Mar 2023	22	1042	754	371	2189	662	78	1	1449	2189
Mar 2024	22	1047	636	486	2191	643	66	1	1482	2191
Mar 2025	22	934	582	509	2047	633	57	1	1357	2047
Mar 2026	19	563	0	30	612	3	0	13	595	612

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	144	-60	-61	23
Mar 2016	169	-77	-89	3
Mar 2017	199	-18	-204	-24
Mar 2018	65	-29	-40	-4
Mar 2019	239	-26	-201	12
Mar 2020	286	-33	-252	1
Mar 2021	21	-29	11	4
Mar 2022	95	17	-119	-8
Mar 2023	133	52	-186	0
Mar 2024	225	-17	-205	2
Mar 2025	169	-42	-128	-1
Mar 2026	-417	1205	-699	89

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	99	107	112	119	74	61	89	98	67	82	—	—
Inventory Days	253	260	270	226	150	192	185	197	212	215	—	—
Days Payable	146	154	167	142	79	104	108	112	100	127	—	—
Cash Conversion Cycle	207	213	215	203	145	149	166	183	178	170	—	—
Working Capital Days	40	41	46	67	46	53	6	73	77	63	—	—
ROCE %	11%	10%	10%	9%	10%	8%	3%	5%	-0%	6%	0%	0%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of NECTAR LIFESCIENCES LTD. (NECLIFE)?

The reported market capitalisation for NECTAR LIFESCIENCES LTD. (NECLIFE) is ₹205Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of NECLIFE?

The current price shown for NECTAR LIFESCIENCES LTD. (NECLIFE) on Fincrux is ₹10.5 with a 52-week high/low of ₹22.5/9.20.

What were NECLIFE latest quarterly results?

For Jun 2026, NECTAR LIFESCIENCES LTD. (NECLIFE) reported sales ₹0 Cr and net profit ₹-13 Cr (figures in ₹ crore unless noted).

What are NECLIFE annual sales and net profit?

For TTM, NECTAR LIFESCIENCES LTD. (NECLIFE) shows sales of ₹7 Cr and net profit of ₹-243 Cr on the Fincrux profit & loss statement.

Who owns NECTAR LIFESCIENCES LTD. (NECLIFE)?

Latest shareholding for NECTAR LIFESCIENCES LTD. (NECLIFE) on Fincrux: Promoters 51.84% (Sep 2026), FIIs 0.50% (Sep 2026), DIIs 0.00% (Sep 2026), Government 3.92% (Sep 2026), Public 43.74% (Sep 2026).

Where can I find NECTAR LIFESCIENCES LTD. (NECLIFE) financials?

NECTAR LIFESCIENCES LTD. (NECLIFE) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show NECLIFE balance sheet and cash flow?

Yes. The NECTAR LIFESCIENCES LTD. (NECLIFE) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 8:39